Pioneering Innovation at AbbVie’s R&D Sites

AbbVie is headquartered in North Chicago, IL. Here, we take on some of the world's most complex diseases, focusing on immunology, oncology and neuroscience. Our headquarters covers the full spectrum of research and development from the initial idea to the finished product.

Our headquarters is also home to our drug discovery engine, which drives our existing and novel therapeutic platforms, and our Genomics Research Center, which translates genetic information into a more personalized approach to medicines. It’s also home to other areas of expertise, including regulatory affairs, patient safety, manufacturing, process chemistry, solid state chemistry, process engineering, medical affairs, and quality assurance.

Take a virtual tour

Our Irvine site is home to our Center of Excellence for aesthetics, neurotoxins, neuro-psychiatry, migraine and eye care research. The 54-acre, 1,000,000-square-foot campus offers unique scientific expertise in the research and development of translational and pharmaceutical sciences to deliver patient-centric, innovative medicines.

AbbVie's Cambridge Crossing site is a 120,000-square-foot facility located in the Cambridge, Massachusetts biotech corridor. This site is dedicated to all aspects of drug discovery and development for diseases in neuropsychiatry and neurology.  Our scientists are focused on understanding the biological mechanisms underlying neuroscience diseases and translating this knowledge to therapies that have the potential to help a broad population of patients with significant unmet needs.  This site houses a broad array of teams involved in the discovery, development, and commercialization of the next breakthroughs for patients. 

Take a virtual tour

AbbVie Waltham Area (AWA) site consists of a community of colleagues that work to advance science and make a remarkable impact on patient care. The team’s primary focus is industry-leading oncology R&D, particularly leadership in antibody-drug conjugate therapy development, which supports AbbVie’s ambition to elevate the standard of care for patients.

For over 30 years, the AbbVie Bioresearch Center in Worcester, Massachusetts, has been an industry leader in drug discovery, development sciences and biologics research. This 553,000-square-foot facility focuses on biotherapeutics development and explores innovative solutions for some of the toughest challenges in medicine, including immunology and neuroscience.

Take a virtual tour

At our integrated facility in Ludwigshafen, Germany, we carry out every step of drug research, development and production. Here, scientists look for ways to treat neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and pioneer new methods of formulating complex compounds to make better medicines possible.

Ludwigshafen also contributes to the digitalization of research by utilizing artificial intelligence, machine learning, bioinformatics and other technologies that enable preclinical and clinical studies worldwide.

Take a virtual tour

AbbVie's Tokyo R&D site is home to our full clinical development capabilities. To obtain NDA approvals for AbbVie's products for Japanese patients, we conduct studies in parallel from phase 1 to phase 4. We perform strategic clinical planning functions for each focus area to develop the Japan-specific development strategy across oncology, immunology, neuroscience, specialty, eye care and aesthetics.